2489589-60-6

2489589-60-6 structure

Name: Pegozafermin
Chemical Name: Pegozafermin
CAS Number: 2489589-60-6
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Inflammation/Immunology
Create Date: 2022-10-12 18:28:45
Modify Date: 2025-06-20 14:44:37
Pegozafermin is a fibroblast growth factor FGF21 (HY-P7012) analog, which is an endogenous metabolic hormone and regulates energy expenditure and glucose and lipid metabolism. Pegozafermin decreases the level of triglyceride (TG), can be used for non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG)[1][2].

Name	Pegozafermin

Description	Pegozafermin is a fibroblast growth factor FGF21 (HY-P7012) analog, which is an endogenous metabolic hormone and regulates energy expenditure and glucose and lipid metabolism. Pegozafermin decreases the level of triglyceride (TG), can be used for non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG)[1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology Research Areas >> Metabolic Disease
In Vitro	High levels of triglyceride (TG) can lead to organ failure, increases risk of cardiovascular disease and acute pancreatitis[1]. Pegozafermin can cause consistent, significant decreases in triglycerides (TG), as well as improvements in hepatic fat and glycemic control[2].
References	[1]. Geng L, et al. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020 Nov;16(11):654-667. [2]. Juan Pablo Frias, et al. BIO89-100 Demonstrated Robust Reductions in Liver Fat and Liver Fat Volume (LFV) by MRI-PDFF, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH. Journal of the Endocrine Society. 2021;5(S1): A5-A6.

No Any Chemical & Physical Properties